ErbB3在骨肉瘤细胞株Saos-2中的表达及其意义

doi:10.3760/cma.j.issn.1673-422X.2016.08.008

摘要/Abstract

摘要： 目的探讨ErbB3在骨肉瘤细胞Saos-2中的表达及其意义。方法实时定量PCR检测骨肉瘤细胞Saos-2和正常人类成骨细胞N704中ErbB3 mRNA的表达水平，Western blotting检测ErbB3蛋白表达水平。使用短发夹RNA（shRNA）构建ErbB3表达沉默的Saos-2细胞，检测0~3 d内Saos-2细胞数目。测定ErbB3表达沉默和正常Saos-2细胞在0～100 μmol/L紫杉醇下48 h存活率。结果相对于正常人类成骨细胞N704，骨肉瘤细胞Saos-2的ErbB3 mRNA表达量增加（4.15±0.04）倍，差异有统计学意义(t=7.31，P＜0.05)，且ErbB3蛋白水平显著增加。ErbB3沉默能降低Saos-2细胞的增殖水平，培养第3天ErbB3沉默的Saos-2细胞数目为（2.22±0.29）万个，而未沉默细胞数目为（4.58±0.41）万个，差异有统计学意义(t=8.23，P＜0.05)。此外，ErbB3沉默能降低Saos-2细胞对紫杉醇的耐受，给药紫杉醇20 μmol/L时，ErbB3沉默组细胞存活率为（43.2±4.7）%，而未沉默组存活率为（61.4±5.9）%，差异有统计学意义(t=6.74，P＜0.05)。结论骨肉瘤细胞Saos-2高度表达ErbB3，ErbB3的表达可增强Saos-2细胞的增殖能力，同时增强Saos-2细胞对紫杉醇的耐受。

关键词: 骨肉瘤, RNA干扰, 紫杉醇

Abstract: Objective To explore the expression of ErbB3 in osteosarcoma cell lines Saos-2 and its significance. Methods Real-time quantitative PCR was used to detected ErbB3 mRNA expression in osteosarcoma cell lines Saos-2 and normal human osteoblasts cell lines N704, and Western blotting was used to detected ErbB3 protein expression. Short hairpin RNA was used to construct ErbB3 knockdown cells and the cell count in 0-3 d was detected. The 48 h survival rates of ErbB3 knockdown cells and normal Saos-2 cells were detected in the presence of 0-100 μmol/L paclitaxel. Results Real-time quantitative PCR showed significant enhanced ErbB3 mRNA expression in Saos-2 cells compared with N704 ［(4.15±0.04) times, t=7.31, P＜0.05］, and Western blotting showed significant enhanced ErbB3 expression in Saos-2 cells compared with N704. As compared with normal Saos-2 cells, ErbB3 knockdown could reduce the Saos-2 cells proliferation, at the first three days in culture, the Saos-2 cell number of ErbB3 silent was (22.2±2.9) thousand, and the control was (45.8±4.1) thousand, with statistical significance (t=8.23, P＜0.05). Moreover, ErbB3 knockdown could reduce the Saos2 cells tolerance to paclitaxel, when treated with 20 μmol/L paclitaxel, surviving cells in ErbB3 silent group was (43.2±4.7)%, and the control was (61.4±5.9)%, with statistical significance (t=6.74，P＜0.05). Conclusion ErbB3 highly expresses in Saos-2 cells, ErbB3 expression can enhance the proliferation of Saos-2 cells and the tolerance of Saos-2 cells to paclitaxel.

Key words: Osteosarcoma, RNA interference, Paclitaxel

王伟,李召辉,郑晓霞,崔玉英. ErbB3在骨肉瘤细胞株Saos-2中的表达及其意义[J]. 国际肿瘤学杂志, 2016, 43(8): 593-596.

Wang Wei, Li Zhaohui, Zheng Xiaoxia, Cui Yuying. Expression of ErbB3 in osteosarcoma cell lines Saos-2 and its significance[J]. Journal of International Oncology, 2016, 43(8): 593-596.

参考文献

［1］杨澄, 苏宏伟, 任慧文, 等. 骨肿瘤的发生发展及转移［J］. 国际肿瘤学杂志, 2014, 41(7): 533536. DOI: 10.3760/cma.j.issn.1673-422X.2014.07.016. ［2］ Zhao S, Kurenbekova L, Donehower L A, et al. Novel mouse models to investigate the molecular pathogenesis of metastatic osteosarcoma［J］. Cancer Research, 2013, 73(8 Suppl): 3867-3867. DOI: 10.1158/1538-7445.AM20133867. ［3］ Kapinas K, Lowther KM, Kessler CB, et al. Bone matrix osteonectin limits prostate cancer cell growth and survival［J］. Matrix Biol, 2012, 31(5): 299-307. DOI: 10.1016/j.matbio.2012.03.002. ［4］ Fisher MC, Clinton GM, Maihle NJ, et al. Requirement for ErbB2/ErbB signaling in developing cartilage and bone［J］. Dev Growth Differ, 2007, 49(6): 503513. DOI: 10.1111/j.1440-169X.2007.00941.x. ［5］ Liu Y, Ma YH, Sun ZZ, et al. Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies［J］. Tumour Biol, 2014, 35(9): 89398943. DOI: 10.1007/s13277-014-2165-9. ［6］张宁, 尤建宇, 国维纳, 等. 骨肉瘤基因治疗的现状分析［J］. 国际肿瘤学杂志, 2015, 42(1): 74-76. DOI: 10.3760/cma.j.issn.1673-422X.2015.01.020. ［7］陆彪. ErbB2的表达与骨肉瘤患者存活率的相关性［J］. 武汉大学学报: 医学版, 2014, 35(2): 273-276. ［8］肖兰, 崔文, 李智敏, 等. MDR1及MDR3短发夹RNA逆转乳腺癌细胞阿霉素耐药的实验研究［J］. 国际肿瘤学杂志, 2008, 35(3): 231-235. ［9］张春林, 曾炳芳, 董扬, 等. 紫杉醇对人骨肉瘤细胞凋亡及对 bcl-2、bax 基因表达的影响［J］. 肿瘤防治研究, 2007, 34(8): 572-575. DOI: 10.3971/j.issn.10008578.2007.08.007. ［10］张素领, 李贵霞, 张丽霞, 等. 紫杉醇脂质体诱导骨肉瘤细胞MG-63凋亡及其机制的研究［J］. 河北医科大学学报, 2013 (1): 40-43, 125. ［11］ Issa A, Gill JW, Heideman MR, et al. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models［J］. Breast Cancer Res, 2013, 15(1): R8. DOI: 10.1186/bcr3379.

[1]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[2]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[3]	马小平, 常君丽, 孙星媛, 杨燕萍. 长非编码RNA调控骨肉瘤耐药机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 51-54.
[4]	周仁邦, 张仲传, 许志远, 朱勋兵. miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[5]	关格格, 孙秋实, 王越华, 陈德杰, 梁金娥. 白蛋白紫杉醇治疗晚期乳腺癌的疗效和安全性分析[J]. 国际肿瘤学杂志, 2022, 49(11): 671-676.
[6]	李炳亮, 杨娅, 黄英丽, 司文, 李兴伟, 张元民, 卞继超, 陈语. miR-20a-5p靶向KDM6B对骨肉瘤细胞增殖、迁移和侵袭能力的影响[J]. 国际肿瘤学杂志, 2021, 48(2): 65-73.
[7]	周丽亚, 李小利, 曹子肖, 向俊馨, 刘佳慧, 夏雪梅, 李殿明. 白蛋白结合型紫杉醇与培美曲塞分别联合顺铂治疗驱动基因阴性晚期肺腺癌的临床观察[J]. 国际肿瘤学杂志, 2021, 48(10): 596-601.
[8]	高爽, 胡长路. 阿帕替尼联合白蛋白结合型紫杉醇治疗老年复发转移性胃癌的疗效及安全性评价[J]. 国际肿瘤学杂志, 2020, 47(11): 669-674.
[9]	周平, 陈伟思, 张爽, 林冰, 潘涛, 刘沙. 紫杉醇同期放疗治疗鼻咽癌肝转移的疗效观察[J]. 国际肿瘤学杂志, 2019, 46(6): 327-330.
[10]	杨晓1,李思2,彭锦3,王琳4,吴衣论4,冯颖2. 质膜型唾液酸酶NEU3活性对骨肉瘤MG-63细胞增殖与凋亡的影响[J]. 国际肿瘤学杂志, 2019, 46(4): 193-198.
[11]	贺启华. 微小RNA-24对骨肉瘤细胞U2OS体外增殖与迁移能力的影响及作用机制[J]. 国际肿瘤学杂志, 2017, 44(7): 490-495.
[12]	侯晓芸,褚燕君. RNA干扰技术治疗肝癌的作用机制[J]. 国际肿瘤学杂志, 2017, 44(4): 297-299.
[13]	袁源, 李松霖, 王忠华, 沈会华, 李悟, 王卫东. 吴茱萸碱抑制Wnt/β-catenin信号通路诱导骨肉瘤MG-63细胞凋亡[J]. 国际肿瘤学杂志, 2017, 44(2): 86-90.
[14]	安成，张焕江. 紫杉醇联合顺铂同期放疗治疗初治局部晚期食管鳞状细胞癌患者的Ⅱ期临床研究[J]. 国际肿瘤学杂志, 2017, 44(10): 736-739.
[15]	王伟,任必勇. 重组人血管内皮抑制素联合TP方案在晚期EGFR野生型肺鳞状细胞癌患者的疗效观察[J]. 国际肿瘤学杂志, 2017, 44(10): 745-748.